在白血病和固体瘤中治疗性向染色质变化
Florian Perner1,2, Tobias Berg2,3, Daniel Sasca2,4
1Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School (MHH), Hannover, Germany.
International journal of cancer
|April 4, 2025
概括
向的表观遗传疗法,包括基因组甲基化和染色质重塑复合物的抑制剂,正在彻底改变癌症治疗. 这些选择性药物为各种癌症提供了新的希望,超越了旧的,不那么具体的方法.
科学领域:
- 表观遗传学和癌症治疗方法
- 染色素生物学和药物开发
背景情况:
- 染色质变化是癌症发展,进展和治疗耐药性的关键驱动因素.
- 表观遗传修饰,如基因组翻译后修饰,越来越多地被认为是治疗点.
研究的目的:
- 审查针对癌症的针对性表观遗传疗法的当前发展情况.
- 要突出针对染色质修饰酶和复合物的抑制剂的近期进展.
主要方法:
- 对各种表观遗传抑制剂的临床前和临床试验数据的摘要.
- 专注于向激素甲基化的抑制剂 (例如,Menin-KMT2A,DOT1L,KDM1A,PRMT5),IDH1/2和SWI/SNF复合体.
- 综合疗法方案和正在进行的临床试验的审查.
主要成果:
- 美国食品和药物管理局批准IDH1/2抑制剂用于特定癌症 (质瘤,胆管癌,骨髓瘤恶性瘤).
- 对Menin-KMT2A,DOT1L,KDM1A,Polycomb,PRMT5和SWI/SNF组件的选择性抑制剂的开发.
- 目前正在进行的临床试验探索组合疗法和新的表观遗传点.
结论:
- 针对性表观遗传疗法代表了癌症治疗的范式转变,朝准确医学迈进.
- 染色体相关过程的抑制剂在瘤学中发挥着越来越重要的作用.
- 未来的研究方向重点是改进选择性抑制剂和优化组合策略.
相关概念视频
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Spreading of Chromatin Modifications
8.1K
The histone proteins in the nucleosomes are post-translationally modified (PTM) to increase or decrease access to DNA. The commonly observed PTMs are methylation, acetylation, phosphorylation, and ubiquitination of lysine amino acids in the histone H3 tail region. These histone modifications have specific meaning for the cell. Hence, they are called "histone code". The protein complex involved in histone modification is termed as "reader-writer" complex.
Writers
The writer...
Writers
The writer...
8.1K
Tumor Immunotherapy
432
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
432
Epigenetic Regulation
3.0K
Epigenetic changes alter the physical structure of the DNA without changing the genetic sequence and often regulate whether genes are turned on or off. This regulation ensures that each cell produces only proteins necessary for its function. For example, proteins that promote bone growth are not produced in muscle cells. Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
X-chromosome...
X-chromosome...
3.0K
Chromatin Modification in iPS Cells
1.6K
Chromatin modification alters gene expression; therefore, scientists can add histone-modifying enzymes, histone variants, and chromatin remodeling complexes to somatic cells to aid reprogramming into pluripotent stem (iPS) cells.
Compact chromatin makes reprogramming difficult. Enzymes, such as histone demethylases and acetyltransferases, are often added during reprogramming to loosen the chromatin, making the DNA more accessible to transcription factors. Molecules that inhibit histone...
Compact chromatin makes reprogramming difficult. Enzymes, such as histone demethylases and acetyltransferases, are often added during reprogramming to loosen the chromatin, making the DNA more accessible to transcription factors. Molecules that inhibit histone...
1.6K


